🔎 Trials Near Me

홈 › 비소세포폐암 › 뉴햄프셔

뉴햄프셔의 비소세포폐암 임상 시험

비소세포폐암 관련 연구 17개가 뉴햄프셔 내 여러 지역에서 참여자를 모집하고 있습니다.

뉴햄프셔의 도시

공식 연구 텍스트(영어)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT04267848

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Dartmouth-Hitchcock Medical Center, Lebanon
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06881784

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Lebanon
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • Dartmouth Hitchcock Medical, Lebanon
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06119581

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04165798

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 3. 업데이트됨 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
피험자 모집 중2상
18 Minutes · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT06031688

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  • Dartmouth Hitchcock, Lebanon
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT06362369

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

  • Dartmouth Hitchcock Medical Center, Lebanon
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 20. 업데이트됨 · NCT05948865

ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.